371 related articles for article (PubMed ID: 12409716)
1. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
[TBL] [Abstract][Full Text] [Related]
2. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
3. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
4. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
[TBL] [Abstract][Full Text] [Related]
5. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
6. Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group.
Prezioso D; Lotti T; Montironi R; Polito M
Eur Urol; 1999; 35 Suppl 1():17-21; discussion 22. PubMed ID: 10081698
[TBL] [Abstract][Full Text] [Related]
7. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.
Klotz LH; Goldenberg SL; Jewett M; Barkin J; Chetner M; Fradet Y; Chin J; Laplante S
Urology; 1999 Apr; 53(4):757-63. PubMed ID: 10197852
[TBL] [Abstract][Full Text] [Related]
8. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
[TBL] [Abstract][Full Text] [Related]
9. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
10. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
[TBL] [Abstract][Full Text] [Related]
11. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
12. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
Rabbani F; Goldenberg SL; Klotz LH
J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
14. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
Lefkowitz GK; Taneja SS; Brown J; Melamed J; Lepor H
J Urol; 2002 Oct; 168(4 Pt 1):1415-8. PubMed ID: 12352407
[TBL] [Abstract][Full Text] [Related]
15. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
16. Initial high-grade prostatic intraepithelial neoplasia with carcinoma on subsequent prostate needle biopsy: findings at radical prostatectomy.
Al-Hussain TO; Epstein JI
Am J Surg Pathol; 2011 Aug; 35(8):1165-7. PubMed ID: 21716083
[TBL] [Abstract][Full Text] [Related]
17. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
Noguchi M; Noda S; Nakashima O; Kojiro M
Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
[TBL] [Abstract][Full Text] [Related]
18. Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer.
Yee DS; Narula N; Ramzy I; Boker J; Ahlering TE; Skarecky DW; Ornstein DK
Arch Pathol Lab Med; 2007 Jun; 131(6):902-8. PubMed ID: 17550317
[TBL] [Abstract][Full Text] [Related]
19. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
20. Prostatic adenocarcinoma with glomeruloid features.
Pacelli A; Lopez-Beltran A; Egan AJ; Bostwick DG
Hum Pathol; 1998 May; 29(5):543-6. PubMed ID: 9596281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]